Benzinga | Dec 13, 2021 04:06PM EST

Adaptive Biotechnologies Announces New Data Demonstrating The Benefit Of Serial MRD Testing With The clonoSEQ Assay In Patients With Blood Cancers At The 63rd ASH Annual Meeting

* Analysis of the MASTER trial (Abstract 481) showed clonoSEQ's ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients

* Data in more than 30 abstracts supports clonoSEQ as a standard of care in blood cancers, delivering relevant and timely clinical insights to physicians, patients and investigators